GSK to acquire Nuvalent for $10.6 billion to expand lung cancer portfolio EP News Bureau Jun 10, 2026 The deal adds zidesamtinib, neladalkib and NVL-330 to GSK’s oncology pipeline, with two products currently under FDA review for…
